Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Long-Term Investments (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 4 years of Long-Term Investments data on record, last reported at $8.1 million in Q4 2025.

  • For Q4 2025, Long-Term Investments fell 35.29% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, down 35.29%, while the annual FY2025 figure was $8.1 million, 35.29% down from the prior year.
  • Long-Term Investments reached $8.1 million in Q4 2025 per MIRM's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $20.9 million in Q1 2025 and bottomed at $2.5 million in Q3 2025.
  • Average Long-Term Investments over 3 years is $12.2 million, with a median of $13.8 million recorded in 2021.
  • The widest YoY moves for Long-Term Investments: up 0.22% in 2025, down 73.5% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $5.0 million in 2021, then skyrocketed by 151.37% to $12.5 million in 2024, then crashed by 35.29% to $8.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $8.1 million in Q4 2025, $2.5 million in Q3 2025, and $17.1 million in Q2 2025.